wilson htm have come out with a report on acrux saying that...

  1. 461 Posts.
    wilson htm have come out with a report on acrux saying that evamist has been the second best launch of a transdermal product in america.currently new prescription rate of 750 per week.they have put a twelve months target of $2.27.this looks good for the company to sell evamist and other products around the world
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.6¢
Change
0.000(0.00%)
Mkt cap ! $6.548M
Open High Low Value Volume
1.6¢ 1.6¢ 1.6¢ $2 103

Buyers (Bids)

No. Vol. Price($)
6 351996 1.6¢
 

Sellers (Offers)

Price($) Vol. No.
1.7¢ 358041 1
View Market Depth
Last trade - 14.28pm 11/08/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.